Description
Clofarabine is a second-generation nucleoside analog of adenosine. Clofarabine inhibits DNA polymerase and ribonucleotide reductase through binding in the A-site, preventing DNA synthesis. Clofarabine is clinically used to treat acute lymphoblastic leukemia (ALL) and is in clinical trials as a potential treatment for other leukemias. Clofarabine exhibits anticancer chemotherapeutic activity, acting as a cytotoxic agent. Clofarabine also binds A1, A2, and A3 adenosine receptors.
References
Robak P, Robak T. Older and new purine nucleoside analogs for patients with acute leukemias. Cancer Treat Rev. 2013 Dec;39(8):851-61. PMID: 23566572.
Jensen K, Johnson LA, Jacobson PA, et al. Cytotoxic purine nucleoside analogues bind to A1, A2A, and A3 adenosine receptors. Naunyn Schmiedebergs Arch Pharmacol. 2012 May;385(5):519-25. PMID: 22249336.
Majda K, Lubecka K, Kaufman-Szymczyk A, et al. Clofarabine (2-chloro-2'-fluoro-2'-deoxyarabinosyladenine)--biochemical aspects of anticancer activity. Acta Pol Pharm. 2011 Jul-Aug;68(4):459-66. PMID: 21796927.
Aye Y, Stubbe J. Clofarabine 5'-di and -triphosphates inhibit human ribonucleotide reductase by altering the quaternary structure of its large subunit. Proc Natl Acad Sci U S A. 2011 Jun 14;108(24):9815-20. PMID: 21628579.
Parker WB, Shaddix SC, Chang CH, et al. Effects of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5'-triphosphate. Cancer Res. 1991 May 1;51(9):2386-94. PMID: 1707752.